The most recently-approved class of agents to treat type 2 diabetes in Taiwan is dipeptidyl
peptidase-4 (DPP-4) inhibitors, most popularly sitagliptin. Commonly reported adverse …

A 55-year-old Japanese man with a 3-year history of type 2 diabetes mellitus was admitted
to our hospital for upper abdominal pain. Control of diabetes mellitus was good with …

Sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, enhances control of type 2 diabetes
by prolonging the duration of active incretin hormones such as glucagon-like peptide 1 (GLP …

In 2007 a question was raised about the causal relationship between the first of the
glucagon-like peptide 1 receptor agonists, exenatide, and pancreatitis, as postmarketing …

Discussion: Acute pancreatitis is an important and fatal side effect of DPP-4 inhibitors. This
was recognized by FDA in 2009 after 88 post-marketing cases of acute pancreatitis in …

Objective To describe the first reported case of acute pancreatitis in a patient receiving
vildagliptin. Methods We present the clinical, biochemical, and radiographic findings of the …

Medication-induced pancreatitis is an overlooked cause of acute pancreatitis. We present an
81-year-old male patient with acute sharp epigastric pain radiating to his back, who was …

Background There is still lack of definite evidence to establish the association between
sitagliptin use and acute pancreatitis. The study aimed to test this issue in Taiwan. Methods …

Recent case reports of acute pancreatitis in patients with type 2 diabetes (T2DM) treated
with incretin‐based therapies have triggered interest regarding the possibility of a …

Acute pancreatitis (AP) is characterised by inflammatory destruction of the gland due to early
activation of the pancreatic proteolytic enzymes. Drug-induced AP accounts for only 0.1-2 …